Fagron Sa · EURONEXT:FAGR
Fagron Sa — Fagron Sa Ord — Q1 2019 Earnings Presentation
9 slides from Fagron Sa's earnings presentation, Apr 12, 2019
Slide 1: Trading Update Q1-2019
Trading Update Q1-2019 Rafael Padilla Chief Executive Officer Karin de Jong Chief Financial Officer Together we create the future April 12, 2019 of personalized medicine
Slide 2: Headlines Q1-2019
Headlines Q1-2019 (x € 1,000) Q1 2019 Q1 2018 ∆ Fagron 121,681 107,342 +13.4% HL Technology 1,723 1,729 -0.3% Total 123.405 109.071 +13.1% • Turnover +12.7% CER • Organic turnover +7.1% CER • Strong growth in North and South America • Brands realized organic turnover growth of 14.8% CER • Further gr
Slide 3: Turnover development
Turnover development Excluding HL Technology 125 120 121.7 6.6 115 4.4 -0.1 110 3.2 105 107.3 0.3 100 95 90 85 80
Slide 4: Fagron Europe
Fagron Europe (x € 1,000) Q1 2019 Q1 2018 Org. growth Org. growth CER Turnover 63,499 63,524 0.0% +0.4% • Organic turnover +0.4% CER • Brands represent 12.1% of turnover – growth of 22.3% in Q1-19 • Successful launch of Fagron Genomics • € 1.5m negative turnover impact due to the temporary reduction
Slide 5: Fagron South America
Fagron South America (x € 1,000) Q1 2019 Q1 2018 Org. growth Org. growth CER Turnover 25,210 23,846 +5.7% +13.2% • Organic turnover +13.2% CER • Growth driven by: • Underlying market growth • Good product availability of Essentials • Focus on innovative Brands
Slide 6: Fagron North America
Fagron North America (x € 1,000) Q1 2019 Q1 2018 Org. growth Org. growth CER Turnover 32,973 19,972 +32.3% +21.9% • Organic turnover +21.9% CER • FCS performing in line with expectations • Organic growth of 23.9% CER • Wichita (FSS) facilities grew 44.1% CER • AnazaoHealth facilities grew 13.2% CER
Slide 7: Summary & Outlook 2019
Summary & Outlook 2019 • Turnover growth driven by strong growth in North and South America • Focus remains on: • Strong innovation-driven organic growth • Disciplined acquisition strategy • Strategic focus on innovation and quality improves competitive advantage • Further growth of turnover and pro
Slide 8: Q&A
Q&A
Slide 9: Disclaimer
Disclaimer Important information about forward-looking statements Certain statements in this presentation may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Compan